Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients with EGFRvIII-positive glioblastoma.
Introduction
Glioblastoma is the most common malignant primary brain tumour in adults. Its annual incidence is more than three per 100 000 people worldwide without major regional variation, and men are affected more frequently than women. 1 The standard of care-maximum feasible surgical resection followed by radiotherapy with concomitant and maintenance temozolomide chemo therapy-generally leads to a median overall survival of about 15 months. 2, 3 The tumourtreating fields device, recently reported to extend survival to 20·5 months, represents an additional treatment option for glioblastoma. 4 Treatment at recurrence, which might include second surgery, re irradiation, alkylating chemotherapy using nitrosoureas such as lomustine or temozolomide rechallenge, or antiangiogenic therapy using bevacizumab, is less well standardised and has not shown a significant improvement in survival in a randomised trial. Poor prognostic factors include poor performance status, older age, incomplete resection, and an unmethylated promoter of the DNA repair gene, O⁶methylguanineDNA methyltransferase (MGMT). Novel treatment approaches to glioblastoma are therefore urgently needed, and immunotherapy has now become the major area of clinical research.
The EGFR gene is amplified in more than 40% of glioblastomas, and EGFR amplification is frequently associated with a deletion mutation affecting exons 2-7, referred to as EGFRvIII or deltaEGFR. EGFRvIII expression occurs in roughly 20-30% of all glio blastomas. [5] [6] [7] The potential immunogenicity of the EGFRvIII mutation, first recognised several decades ago, resulted in the development of rindopepimut-a peptide vaccine containing the specific novel aminoacid sequence created by the EGFRvIII deletion mutation conjugated to keyhole limpet haemocyanin. Rindopepimut has been explored in two small singlegroup phase 2 trials, ACTIVATE 8 and ACT II, 9 as well as a larger phase 2 trial ACT III, 6 which was initially planned as an openlabel, randomised phase 3 trial but was converted to a singlegroup design after nearcomplete voluntary attrition of the first 16 patients randomly assigned to receive temo zolomide alone. In these trials, about 100 patients with EGFRvIIIexpressing glioblastoma who had received a gross total resection and had no evidence of progression after radiotherapy with concomitant temozolomide were given rindopepimut alone (ACTIVATE) or rindopepimut with adjuvant temo zolomide (ACT II and ACT III). The results of these three trials showed a consistent and encouraging progressionfree survival in the range of 15 months from diagnosis and overall survival of 24 months from diagnosis, which compared favourably with contemporary patient cohorts who received standard treatment (appendix p 8). The selection of patients with minimal residual disease (MRD) in all these trials after completion of chemoradiation was based on the assumption that MRD would minimise the tumour associated immuno suppression typical of glioblastoma.
ACT IV was designed as a pivotal, randomised, placebo controlled, phase 3 clinical trial to assess whether or not
Research in context
Evidence before this study We searched PubMed for scientific literature published in English before Aug 1, 2011, using the search terms "glioblastoma" and publication type "randomized controlled trial" or "clinical trial, phase III". The standard of care for newly diagnosed glioblastoma established in 2005-maximum feasible surgical resection followed by radiotherapy and temozolomide chemotherapy-is associated with median overall survival of about 15 months. Despite the introduction of several investigational approaches in the subsequent years, no treatment has successfully shown further improvements in survival. The addition of the search term "EGFRvIII" and expansion of our search to any clinical trial did not identify any other agents specifically targeting EGFRvIII. Finally, a search including "glioblastoma", "EGFRvIII", and "survival" produced a few retrospective studies showing similar or worse median and long-term survival for patients whose tumour expressed EGFRvIII. Three previous studies of rindopepimut have been done in patients with newly diagnosed, EGFRvIII-expressing glioblastoma and minimal residual disease (MRD). In these studies, rindopepimut was associated with a strong anti-EGFRvIII humoral immune response, a notable reduction in EGFRvIII expression in available recurrent tumour samples, and a median survival of 20-22 months, as compared with about 12 months for a small matched contemporary dataset and 15 months for the small subset of patients with newly diagnosed EGFRvIII-expressing glioblastoma randomly assigned to receive standard of care treatment in the ACT III study.
Added value of this study
To our knowledge, ACT IV is the first randomised trial to assess the efficacy of an EGFRvIII-targeted treatment for patients with newly diagnosed glioblastoma. Despite the strong anti-EGFRvIII immune response generated in patients, the primary study analysis did not show a survival benefit for patients with MRD who received rindopepimut with temozolomide versus those who received temozolomide alone. We recorded a potential long-term survival benefit in exploratory analyses of a subset of patients with significant residual disease (SRD), which might challenge the view that minimal tumour burden is required for immunotherapy to be effective. Also notable is that patients in the control group fared markedly better than matched control datasets available at the time of study design, suggesting that glioblastoma outcomes have improved since the study was originally designed.
Implications of all the available evidence
Our results question the utility of immunotherapy targeting a single tumour antigen with heterogeneous tumour expression, as well as the optimal setting for evaluation of immunotherapy. Patients with more substantial residual disease expressing the target antigen might experience greater benefit from generation of targeted immunity than those with completely resected disease. Recent data from a randomised, double-blind, phase 2 study in recurrent EGFRvIII-positive glioblastoma (the ReACT study) suggest a prominent treatment effect (overall survival HR 0·53, 95% CI 0·32-0·88; p=0·013) for rindopepimut when combined with standard bevacizumab versus bevacizumab alone. Its combination with temozolomide might compromise an immunological effect, by contrast with bevacizumab. The results of ACT IV also question the predictive value of both historical control datasets (matched patients from non-study databases) and small randomised phase 2 trial datasets (such as ACT III) as a basis for the design of phase 3 studies. These data lend support to further clinical trials that use combination strategies such as immunotherapy with angiogenesis inhibition.
the addition of rindopepimut to standard temozolomide chemotherapy increased overall survival compared with that for temozolomide alone in patients with newly diagnosed EGFRvIIIexpressing glioblastoma.
Methods

Study design and participants
ACT IV was a randomised, doubleblind, phase 3 study done at 165 hospitals in 22 countries (appendix p 12). The study was open to men and women aged 18 years and older with newly diagnosed EGFRvIIIexpressing glio blastoma. Confirmation of glioblastoma histology and EGFRvIII expression analysis from resected tissue by real time (RT) PCR were done centrally (LabCorp, Research Triangle Park, NC, USA). Patients must have undergone maximal surgical resection and have completed standard radiotherapy (up to 60 Gy) with concomitant temozolomide (75 mg/m² per day). 2 To be eligible, at least 90% of the planned radiotherapy dose had to be delivered. Patients had to have tumour tissue specimens (paraffinembedded) from surgical resection available for central pathology review, MGMT status determination, and analysis of EGFRvIII status. Exclusion criteria were disease progression during chemoradiation, any additional tumourspecific treatment for glioblastoma, inability to taper corticosteroids to 2 mg of dexamethasone or lower (or equivalent) per day for at least 3 days before randomisation, Eastern Cooperative Oncology Group (ECOG) performance status of 3 or higher in the week before randomisation, diffuse leptomeningeal disease, gliomatosis cerebri, infratentorial disease, active infection, metastatic disease, and immunosuppressive disease.
An independent imaging review committee (BioClinica, Princeton, NJ, USA) assessed postoperative and post chemoradiation brain MRIs, and retrospectively classified patients as having either MRD (<2 cm² of residual enhancing tumour on postchemoradiation imaging) or significant residual disease (SRD; ≥2 cm² of residual enhancing tumour on postchemoradiation imaging).
The study was compliant with the Declaration of Helsinki and Good Clinical Practice guidelines. Ethics approval was obtained at all participating centres and all patients provided written informed consent. The full trial protocol can be found in the appendix.
Randomisation and masking
Eligible patients were stratified by MGMT promoter methylation status (methylated vs unmethylated vs unknown), European Organisation for Research and Treatment of Cancer (EORTC) recursive partitioning analysis class (III vs IV vs V), 10, 11 and geographical region (North America and western Europe vs all other regions), and were randomly assigned (1:1) to the treatment groups with a prespecified randomisation sequence with a block size of four. Unblinded pharmacists who were otherwise uninvolved in study conduct obtained randomly assigned treatment assignments and managed study treatment via interactive response technology. Study treatments were prepared in the pharmacy and given to study staff in blinded (label included patient ID and expiry information), preloaded syringes. Keyhole limpet haemocyanin was given as a control injection to produce a local reaction similar to that expected with rindopepimut to maintain the treatment blind. Pharmacovigilance staff at the study funder and contract research organisation received treatment assignments for individual patients when necessary to comply with international safety reporting. Pharmacy records were audited by an independent team of contract research organisation staff. The study data monitoring committee and the supportive independent statistical group at the contract research organisation viewed unblinded data. All other study staff, patients, and investigators remained masked to treatment assignments.
Procedures
All patients received standard maintenance temozolomide administered orally at a dose of 150-200 mg/m² on days 1-5 of each 28day cycle, for 6-12 cycles, 2 or longer if consistent with the local standard of care. Patients randomly assigned to the rindopepimut group also received 500 µg of rindopepimut admixed with 150 µg GMCSF (Leukine, Sanofi Aventis, Bridgewater, NJ, USA), while the control group received 100 µg keyhole limpet haemocyanin (Biosyn, Carlsbad, CA, USA). Each 0·8 mL dose was given as two to eight separate intradermal injections into the skin of the thigh below the groin. The allowance for between two and eight injections allowed for a smaller volume of individual intradermal injections, potentially reducing patient discomfort and risk of leakage. Experimental treatment was started 7-14 days after completion of standard chemoradiation, and was given as two initial priming doses (on study days 1 and 15), then monthly on day 22 of each temozolomide cycle and continuing after the end of maintenance temozolomide until disease progression or intolerance. Because all toxicities related to rindopepimut vaccination were expected to be immunologically mediated, no adjustment to the dose of doubleblind vaccine was allowed; however, dose omission or delay was allowed for toxicity.
Brain MRI scans were done within 14 days after completion of chemoradiation, every 8 weeks for 6 months, every 12 weeks from 6 months through year 2, every 16 weeks from years 2-4, and every 26 weeks thereafter, or until documented disease progression. Tumour response and progression were assessed according to the Response Assessment in Neuro Oncology (RANO) Working Group criteria, 12 with minor modifications for the purpose of protocol standard isation (appendix p 9). Local investigator assessments guided individual treatment decisions. The retrospective imaging review committee assessment, masked to treatment assignment and investigator assessments, was used for the primary analyses of progressionfree survival and objective tumour response.
Safety assessments included monthly physical examination, vital signs, routine laboratory monitoring (haematology on days 1 and 22 of each cycle, and blood chemistry and urinalysis on day 1 of each cycle), and evaluation of adverse events using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 4.0). The MD Anderson Symptom Inventory Brain Tumor (MDASIBT) and EORTC Core Quality of Life Questionnaire (QLQC30) and Brain Cancer Module (BN20) were completed every month throughout treatment by patients who were fluent in a language in which the questionnaires were validated.
To assess EGFRvIII expression, formalinfixed paraffin embedded tumour tissue was analysed centrally (LabCorp, Research Triangle Park, NC, USA). EGFRvIII variant and EGFR wildtype status were ascertained with a Taqman based RTPCR assay done on an ABI Prism (Applied Biosystems Corporation, Foster City, CA, USA) 7900HT instrument. The fluorescence detected was directly proportional to the amount of RNA present and expressed as cycle threshold. We used a predefined cutoff expressed as delta cycle threshold (cycle threshold of EGFRvIII minus that of EGFR wild type) of 11·0 or lower to define a sample as positive for EGFRvIII. The threshold, which was selected as a conservative cutoff to minimise the possibility of including EGFRvIIInegative patients, was defined by the delta cycle threshold values of samples from the ACT III study that showed unambiguous calls of positive (n=9) or negative (n=10) by corroboration of immunohistochemistry and PCR results, confirmed by reproducibility testing and accuracy verification.
To assess MGMT promoter methylation status, formalinfixed paraffinembedded tumour samples were analysed centrally at LabCorp under licence from MDx Health (Irvine, CA, USA) by methylationspecific PCR, based on previously published methods. 13 To assess humoral responses to the vaccine, antibody titres were measured by ELISA with microtitre plates directly coated with a 14aminoacid peptide, which spans the exons 1-8 junction of EGFR and is specific for the EGFRvIII mutant.
14 Dilutions of patient plasma were incubated in the plates, and the antiEGFRvIII antibodies were detected with an Fcγspecific goat antihuman F(abʹ)2 antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch Labs, West Grove, PA, USA) followed by tetramethylbenzidine substrate. Absorbance was measured at wavelength of 450 nm. Patient samples were screened and positive samples titred against a plate specific floating cutoff point. We calculated the antibody titre for patient samples as the highest dilution with an optical density value greater than the mean plus three times the standard deviation (SD) of replicatenegative control samples run on the same plate. Because the starting dilution was 1:100, we reported samples that screened negative with titres lower than 1:100. For post hoc exploratory analyses of survival, patients were retrospectively classified according to the trajectory at which antiEGFRvIII titres developed with rindopepimut treatment (slow, moderate, or rapid).
Typing of HLA class I alleles (A and B loci) and HLA class II alleles (with a -DR locus) by serology or DNAPCR was done by an American Society for Histocompatibility and Immunogeneticsaccredited laboratory (ClinImmune Labs, Aurora, CO, USA) using buccal swab samples.
Outcomes
The primary endpoint was overall survival (defined as the time from randomisation to death) in patients with newly diagnosed, EGFRvIIIpositive glioblastoma and MRD. Patients with SRD formed a second exploratory cohort that had not been included in previous studies; overall survival was assessed in these patients and in the entire patient cohort (all randomised patients) as supportive secondary analyses. Secondary endpoints were progressionfree survival (defined as the time from randomisation to disease progression or death, whichever occurred first), the proportion of patients achieving an objective tumour response (a confirmed complete or partial response according to the RANO criteria), health related quality of life (assessed with the MDASIBT, QLQC30, and BN20), and to further characterise the safety profile and overall immunogenicity of rindopepimut in patients with both MRD and SRD. Correlative endpoints were the specific humoral responses to EGFRvIII and posttreatment EGFRvIII expression status.
Statistical analysis
Patients classified with MRD by the imaging review committee were included in the modified intentiontotreat population for the primary analysis of overall survival. 283 deaths in the MRD population at the time of the final analysis were calculated to provide 80% power to detect a target hazard ratio (HR) of 0·714, which corresponded to a 6month improvement in median overall survival (from 15 months for the control group to 21 months for the rindopepimut group). The target number of deaths was based on a onesided log rank test, overall type I error rate of 0·025, and two planned interim analyses of overall survival for superiority using an O'BrienFleming group sequential monitoring plan. Allowing for a 48month accrual period and 10% attrition rate, a sample size of 374 patients with MRD was expected to result in 283 deaths within 72 months of the first randomly assigned patient. Supportive secondary analyses of overall survival were done for all randomly assigned patients (intentionto treat analysis). To control the familywise error rate (the probability of making one or more false discoveries when performing multiple hypotheses tests), study analyses were to proceed according to a fixed sequence procedure in which the primary analysis was completed for the MRD population (modified intention to treat) and all enrolled patients (intention to treat) sequentially, followed by the secondary endpoint analyses (appendix p 1). According to this analysis plan, each sequential statistical test was to be considered positive only if the previous statistical test was positive. The sample size for patients with SRD was not prospectively defined, and analysis of this population was planned as exploratory. Safety analyses included patients who received at least one dose of study treatment.
Overall survival and progressionfree survival, including landmark survival rates at 1, 2, and 3 years, were summarised using the KaplanMeier method. For overall survival, patients who were still alive or lost to followup at the data analysis cutoff date were rightcensored. The censoring date was defined as the patients' date of last contact or data analysis cutoff date (whichever occurred first). Primary inferential comparisons between treatment Figure 1 : Trial profile *Reasons for failure to enrol were collected via a hard copy screening log, with data for 304 of these 600 patients compiled electronically at the time of study closure. Of these, 143 (47%) declined study participation, 68 (22%) experienced disease progression before study entry, 21 (7%) had a contraindicated concurrent illness or low Eastern Cooperative Oncology Group performance status, 11 (4%) did not receive adequate or standard chemoradiation, 11 (4%) were not candidates for adjuvant temozolomide, ten (3%) were receiving exclusionary doses of corticosteroid, and 40 (13%) were not enrolled for other miscellaneous reasons. GBM=glioblastoma. For diagnostic purposes, the overall survival proportional hazard assumption was checked by comparing the HRs and assessing the significance level of stratification variables from stratified and unstratified Cox models. We explored the interactions between the treatment group and stratification variables by inclusion of the stratification factors as covariates in the unstratified Cox model. In recognition of the delayed treatment effect previously recorded with other immunotherapies, an exploratory analysis using a weighted logrank test was also done. 15 In exploratory correlation analyses of HLA type and outcome, the overall survival and progressionfree survival hazard ratio was calculated between treatment groups within each HLA type, with p value based on type 3 test from Cox model with treatment group, HLA type, and treatment group * HLA type interaction as covariates.
We planned two interim analyses for superiority and futility after 142 and 212 deaths in the MRD population, representing 50% and 75% of the events required for final analysis. The study was designed with a nonbinding approach for efficacy and futility boundaries. Early stopping boundaries for superiority according to an O'BrienFleming alpha spending were a p value of 0·002 for the first interim analysis and a p value of 0·018 for the second interim analysis. The futility analyses were based on the observed treatment effect, with HRs of 1·1 or higher and higher than 0·9, respectively, representing boundaries for futility for the two interim analyses. For the first and second interim analyses, respectively, the chances of stopping a positive study for futility were 0·5% and 4·6% and the chances of stopping a negative study for futility were 29% and 78%, respectively. The data monitoring committee evaluated the preplanned interim analyses. SAS version 9.4 was used for all statistical analyses.
This study is registered with ClinicalTrials.gov, number NCT01480479.
MRD population (primary analysis population)
Intention-to-treat population (all randomly assigned patients) 
SRD population
Rindopepimut
Role of the funding source
The funder designed the study in collaboration with the investigators, managed the clinical trial database including oversight of data collection, performed statistical analyses, and provided medical writing assistance. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Between Jan 26, 2012, and Dec 1, 2014, 4652 patients were screened for study eligibility ( figure 1 ). In the cohort of 4519 patients for whom submitted tumour tissue was adequate for EGFRvIII expression analysis, 1345 (30%) had EGFRvIIIexpressing tumours. Between April 12, 2012, and Dec 15, 2014, 745 eligible patients with EGFRvIIIexpressing tumours were randomly assigned to receive rindopepimut (n=371) or control (n=374). Of these, 405 (195 allocated to rindopepimut and 210 allocated to control) were assigned to the MRD population by central review and included in the primary modified intentiontotreat analysis, and 741 (369 allo cated to rindopepimut and 372 allocated to control) received at least one dose of study treatment and were included in the safety analyses. 338 patients (175 allocated to rindopepimut and 163 allocated to control) had SRD and two were unevaluable (one allocated to each group). Pretreatment patient and disease characteristics for randomly assigned patients were well balanced between treatment groups within each analysis population (table 1) . At the second preplanned interim analysis done after 212 deaths had occurred in the MRD population (data cutoff Oct 24, 2015), the futility boundary was crossed. The overall survival HR for rindopepimut versus control in the MRD population was 0·99 (95% CI 0·74-1·31), suggesting that rindopepimut was unlikely to be better than the control in terms of overall survival. Therefore, the study was closed prematurely, and preliminary primary analysis results were released. Additional survival information was obtained as patients were discontinued from the study, and final analyses were done with a data cutoff of Overall survival did not differ between the treatment groups for the MRD or intentiontotreat populations ( figure 2A, 2B ). Median overall survival in the rindopepimut group was 20·1 months (95% CI 18·5-22·1) versus 20·0 months (18·1-21·9) in the control group in the MRD population (HR 1·01, 95% CI 0·79-1·30; p=0·93), and 17·4 months (16·1-19·4) versus 17·4 months (16·2-18·8), respectively, in the intentiontotreat population (HR 0·89, 95% CI 0·75-1·07; p=0·22). In an exploratory analysis of the SRD population (HR 0·79, 95% CI 0·61-1·02; p=0·066), median overall survival was similar between the treatment groups (14·8 months 
Time since randomisation (months)
Number at risk (number censored)
Rindopepimut + temozolomide Control + temozolomide 195 (0) 210 (0) 190 (0) 210 (3) 150 (3) 169 (6) 102 (12) 101 (24) 42 (39) 53 (41) 21 (50) 21 (62) 7 (61) 7 (69) 4 (62) 4 (71) 0 (66) 0 (75) 371 (0) 374 (0) 345 (1) 347 (3) 261 (5) 268 (7) 159 ( 155 (1) 145 (0) 111 (2) 98 (1) 57 (13) 47 (11) 30 (29) 19 (20) 11 ( figure 2C ).
In the group of patients who were classified with MRD or SRD by investigator assessment (rather than the central reviewer), overall survival also did not differ between treatment groups (appendix p 2). We also performed prespecified and posthoc subgroup analyses of overall survival in the MRD and SRD populations; the findings of these subgroup analyses were consistent with our main findings ( figure 3) .
However, in an exploratory prespecified analysis in the SRD population a difference in longterm survival was recorded, with a 2year overall survival of 30% (95% CI 23-37) in the rindopepimut group versus 19% (13-26) in the control group (p=0·029). However, this difference was not significant when SRD was classified by investigator assessment rather than by central review (appendix p 2).
On sensitivity analysis of overall survival, we noted some violations of the proportional hazard assumption in various strata (data not shown). We explored interactions between the treatment group and stratification variables and found that none of the interaction terms were significant (data not shown). The weighted logrank p values for prespecified weights (r1=0, r2=1, 2) were 0·93 and 0·88 for the MRD population, 0·081 and 0·092 for the intentiontotreat population, and 0·021 and 0·017 for the SRD population, respectively.
The median duration of adjuvant temozolomide treatment within the MRD population was 5·2 months (IQR 3·2-10·3) for the rindopepimut group versus 5·0 months (3·0-10·1) for the control group. The median duration of adjuvant temozolomide within the SRD population was 4·1 months (IQR 2·0-7·3) for the rindopepimut group versus 4·1 months (2·0-6·7) for the control group. Anticancer treatments given in the posttreatment followup were well balanced across treatment groups (appendix p 10), although we noted some geographical differences in the type of anticancer treatments used after progression (appendix p 11), with more frequent use of nitrosoureas in the European Union and more frequent use of bevacizumab in the USA.
Progressionfree survival was similar between treatment groups within the MRD (median progression free survival 8·0 months, 95% CI 7·1-8·5, in the rindopepimut group vs 7·4 months, 6·0-8·7, in the control group; HR 1·01, 95% CI 0·80-1·29; p=0·91), intentiontotreat (7·1 months, 5·4-7·9 vs 5·6 months, 5·1-7·1; 0·94, 0·79-1·13; p=0·51), and SRD (3·7 months, 3·5-5·8 vs 3·7 months, 3·3-4·9; 0·86, 0·66-1·12; p=0·28) populations (appendix p 3). The proportion of patients who achieved an objective tumour response in the responseevaluable population irrespective of MRD or SRD status did not differ between treatment groups (31 [15%, 95% CI 10-21] of 208 in the rindopepimut group and 27 [15%, 95% CI 10-21] of 184 in the control group).
We noted no significant differences between groups in any of the qualityoflife measures (appendix p 4) or requirement for corticosteroids (which formed a part of response assessment) in the analysis populations (appendix p 5).
Rindopepimut treatment led to robust humoral responses, with treated patients reaching a median peak antiEGFRvIII antibody titre of 1:25 600 (IQR 3200-204 800). The magnitude of response was similar between the MRD and SRD populations (appendix p 6). The use of corticosteroids did not seem to have a substantial effect on the rindopepimutinduced humoral immune response (appendix p 7). However, we did not record a consistent association between increasingly rapid titre response and clinical outcome ( figure 3) .
Intensity of tumour EGFRvIII expression (RTPCR delta cycle threshold in the baseline sample) was not associated with outcome ( figure 3 ). In the small subset of patients with available posttreatment tumour sample, EGFRvIII expression established by RTPCR was undetectable after treatment for 21 (57%) of 37 patients given rindopepimut and 23 (59%) of 39 patients in the control group. Mean antiEGFRvIII titre did not differ significantly between the groups of patients with either loss or persistence of tumour EGFRvIII (data not shown). Elimination of EGRFvIII was not associated with with outcome (data not shown).
Correlation analysis of HLA type with outcome was done for the MRD and SRD populations. Although B18, A25, and D11 were each associated with overall survival or progressionfree survival in individual analyses, sample sizes were small, this association was not observed consistently in the analysis populations, and these HLA types would not be predicted to bind to the EGFRvIII peptide based on algorithm analysis of the peptide (data not shown).
Rindopepimut was very well tolerated ( in the control group), and 16 were due to adverse events (9 [4%] in the rindopepimut group and seven [3%] in the control group). One death-a pulmonary embolism in a 64yearold male patient after 11 months of treatmentwas assessed as potentially related to rindopepimut. Eight patients discontinued vaccine treatment due to treatmentrelated toxic effects. These included two cases of hypersensitivity or allergic reaction, two cases of rash, and single cases of bone or muscle pain and the fatal pulmonary thromboembolism in the rindopepimut group, and single cases of rash and depression in the control group. Despite the finding of hypersensitivity reaction attributed to rindopepimut in previous RPA=recursive partitioning analysis. HRs were calculated for the patients given rindopepimut within each classification versus all patients in the control group.*The fluorescence detected was directly proportional to the amount of RNA present and expressed as cycle threshold. EGFRvIII intensity is defined by delta cycle threshold (cycle threshold of EGFRvIII minus that of EGFR wild type). †Humoral response was classified according to the trajectory at which anti-EGFRvIII titres developed with rindopepimut treatment. Favours rindopepimut plus temozolomide Favours control plus temozolomide 1 studies, 6, 8, 9 such events were infrequent in both treatment groups in this study (table 2) . Similary, no evidence suggested increased toxicities that might theoretically have arisen due to rindopepimutinduced immune infiltration of the brain, such as cerebral oedema or seizure (table 2) .
Discussion
The primary analysis of the ACT IV study did not show a survival benefit for patients with EGFRvIIIpositive glioblastoma with MRD who received rindopepimut with temozolomide versus those who received a control. Notably, the definition for MRD was increased to less than 2 cm² of residual enhancing tumour in the ACT IV study, as compared with 1 cm² or less in previous studies. Median overall survival from randomisation for patients with MRD given rindopepimut in ACT IV was 20·1 months, which is consistent with the range of 20-22 months recorded in previous uncontrolled trials in the same population. 6, 8, 9 However, patients in the control group fared substantially better than matched control datasets available at the time of study design (appendix p 8).
Rindopepimut plus temozolomide (n=369)
Control plus temozolomide (n=372) In view of the previous ACT III study in which voluntary attrition of patients randomly assigned to the openlabel control group rendered the original randomised design infeasible, we recognised that a truly blinded design would be crucial for ACT IV. Therefore, rather than an inactive placebo, we used keyhole limpet haemocyanin as a control injection to replicate the local reactions (erythema, pruritus, and rash) experienced by nearly all patients who receive rindopepimut. Keyhole limpet haemocyanin can generate immune activation and one might speculate that the better than expected outcome in the control group might result from the generation of an effective immune response unrelated to EGFRvIII. However, it is generally thought that a tumour specific response triggered by keyhole limpet haemo cyanin would require topical application to the tumour itself (intratumoural injection in this case) and that a genuine therapeutic effect is unlikely to result from peripheral intradermal injection. In a small phase 2 trial of patients with recurrent disease (ReACT), 16 the same keyhole limpet haemocyanin control was used with control group outcome no better than expected. The unexpectedly favourable outcome for the ACT IV control group might also have resulted from enrolment of lower risk patients (ie, patients with favourable prognostic factors) compared with previous trials. However, the eligibility criteria and baseline characteristics of patients in the ACT IV study were similar to the previous phase 2 studies of rindopepimut. 6, 8, 9 Additionally, ACT IV was a large, global phase 3 study, in which outcomes are generally expected to be less favourable than phase 2 studies restricted to specialised centres. Thus, it is more likely that optimisation of standards of care has promoted improvements in outcome over time (appendix p 8). 17 In view of the negative result for the primary analysis and in accordance with the study's sequential analysis plan, all subsequent analyses should be considered exploratory and cannot be interpreted as conclusive. However, an exploratory analysis showing a potential longterm (2year) survival benefit in patients with SRD given rindopepimut versus control is an interesting result that does deserve discussion. No imbalances were identified that might have accounted for this signal of differential activity, since baseline prognostic characteristics, corticosteroid dosing, and subsequent therapies were well balanced between both treatment groups. Yet, this apparent treatment effect in the SRD population was less pronounced when tumour burden was defined by the investigator as opposed to central review, and the magnitude of humoral immune response did not consistently correlate with presumed treatment benefit or extent of residual disease. Although further study is needed, this exploratory finding might challenge the view that minimal tumour burden is required for immunotherapy to be most effective.
In the ReACT study, 16 in which patients were not required to have MRD, rindopepimut was associated with a survival advantage (HR 0·53, 95% CI 0·32-0·88; p=0·013) when combined with bevacizumab. Although humoral responses were similar in patients in the ACT IV study irrespective of the amount of residual tumour present, whether effective cellular responses occurred in these patients is unclear. Perhaps residual disease, which would be associated with increased EGFRvIII expression, is required to generate effective and persistent cellular immunity required for a therapeutic effect. The choice of combination treatment might also account for what seems to be a more prominent treatment effect in the ReACT study than that which might have occurred in the SRD population in ACT IV. VEGF is known to depress tumour immunity and bevacizumab has enhanced immunemediated antitumour effect in nonclinical models. 18 Alternatively, temozolomideinduced lympho penia might reduce the efficacy of an immunotherapy. However, this concept is not supported by the ACT II study, in which patients who received doseintensified temozolomide with rindo pepimut developed more robust EGFRvIIIspecific humoral immune responses, despite more substantial lymphopenia.
An unexpected finding was the loss of EGFRvIII expression in about 60% of the small subset of patients with tumour tissue available at recurrence, irrespective of study treatment received. Loss of EGFRvIII expression has been reported in most patients given rindopepimut, 6, 8, 9 but not in those receiving standardof care chemo radiation. 19 However, contemporary datasets are contradictory. One RNAonlybased study reported frequent loss of EGFRvIII expression with standard therapy, 20 but this was not confirmed in a recent study by the German Glioma Network. 21 Although screening in ACT IV was done by PCR whereas previous studies used immunohistochemistry, the methods have previously shown good concordance. 6 Supposing that the true rate of EGFRvIII loss at recurrence approaches 50%, one might conclude that the survival benefit recorded in the ReACT trial is derived from only half of the patients, and would therefore probably be quite significant in a cohort with confirmed EGFRvIII expression. More importantly, these data suggest that at least a biopsy is required to verify EGFRvIII positivity before patients with recurrent glioblastoma are enrolled into future trials targeting this mutation. However, the ACT IV results, as well as the lack of stability of EGFRvIII and its expression pattern restricted to subpopulations of tumour cells, 5, 21 raise questions about its role as a molecular target for treatment in primary glioblastoma. Trials with other agents in patients with EGFRvIIImutated tumours might provide additional insight and clarity.
To our knowledge, ACT IV was the most comprehensive study of patients with EGFRvIIIexpressing glioblastoma done so far, despite the fact that nearly half of eligible patients declined study participation, probably partly due to the nature of the screening process that allowed for an abbreviated "tissue screening" consent, followed later by the formal study evaluation and consenting process. However, limitations of the study include uncertainties about the significance of the cutoff of EGFRvIII expression for inclusion, and the fact that, because of practical considerations related to patient accrual (that patients would not be identified and screened in time to start study prior to radiation), the vaccine was started after radiotherapy rather than as early as possible. Furthermore, whether concurrent chemotherapy with temozolomide blunts the potential activity of immunotherapy remains controversial. There are some old and some new lessons to be learned from the disappointing outcome of ACT IV. First, even carefully assembled historical controls can be misleading and an unsuitable basis for clinical trial designs, because it is difficult to control for patient selection. Second, even biologically matching data of EGFRvIII loss at progression on antiEGFRvIII treatment need controls. Third, because the humoral response to EGFRvIII was similar to that recorded in previous studies of rindopepimut, the present study does not support these responses as a reliable predictor of outcome and calls for intensified efforts to establish cellular immune responses as a readout. Fourth, the selection of one molecular target of immunotherapy might be insufficient, especially if its expression is not stable and not ubiquitous, and multipeptide vaccines against several targets and non peptides with higher immunogenicity might turn out to be superior. Moreover, the most promising approach seems to be to combine a gliomaspecific stimulus based on well defined antigens with a general activation of the immune system. At present, this can most easily be achieved with checkpoint inhibition or with the neutralisation of strong immunosuppressive factors such as TGFβ. Taken together, the results of the ACT IV and ReACT trials support the design of innovative clinical trials evaluating combination approaches to show efficacy of immuno therapy in glioblastoma.
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